Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes

NCT07904962 · tracked via the Priya Life Science China tracker
Sponsor
China Institute of Sport Science
Phase
Not applicable
Started
2026-11
Last updated
2026-11-03

Condition(s) studied

Prediabetes

Investigational drug(s) / intervention(s)

Combined Aerobic and Resistance Training (3:1)Combined Aerobic and Resistance Training (1:1)Combined Aerobic and Resistance Training (1:3)Standardized Health Education

Combined Aerobic and Resistance Training (3:1): Participants will complete 12 weeks of supervised combined aerobic and resistance training, three sessions per week. Each session will include approximately 60 minutes of main training, consisting of approximately 45 minutes of a standardized low-impact aerobic exercise routine and 15 minutes of resistance training. Training intensity and exercise difficulty will be progressively adjusted according to predefined safety criteria and individual tolerance.

Combined Aerobic and Resistance Training (1:1): Participants will complete 12 weeks of supervised combined aerobic and resistance training, three sessions per week. Each session will include approximately 60 minutes of main training, consisting of approximately 30 minutes of a standardized low-impact aerobic exercise routine and 30 minutes of resistance training. Training intensity and exercise difficulty will be progressively adjusted according to predefined safety criteria and individual tolerance.

Combined Aerobic and Resistance Training (1:3): Participants will complete 12 weeks of supervised combined aerobic and resistance training, three sessions per week. Each session will include approximately 60 minutes of main training, consisting of approximately 15 minutes of a standardized low-impact aerobic exercise routine and 45 minutes of resistance training. Training intensity and exercise difficulty will be progressively adjusted according to predefined safety criteria and individual tolerance.

Standardized Health Education: Participants will receive standardized health education during the 12-week intervention period. The education will provide general information on prediabetes, healthy lifestyles, sleep, smoking and alcohol use, medication adherence, and health and safety. It will not include an individualized structured exercise program or an individualized weight-loss diet prescription.

Study summary

The goal of this clinical trial is to evaluate how different time ratios of aerobic and resistance training affect blood glucose levels and physical health in adults aged 50 years and older with prediabetes. Researchers will compare three combined exercise programs with aerobic-to-resistance training time ratios of 3:1, 1:1, and 1:3 with a health education control group.

Participants in the exercise groups will take part in supervised training three times per week for 12 weeks. Each session will include approximately 60 minutes of aerobic and resistance exercise, with the amount of time spent on each type of exercise differing according to the assigned group. Participants will complete health assessments before and after the 12-week intervention. The main outcome of interest is glycated hemoglobin (HbA1c), which reflects average blood glucose levels over the previous 2 to 3 months. Participants in the control group will receive standardized health education and will not take part in the study-provided structured exercise program during the 12-week intervention period.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 50 years or older. * Body mass index (BMI) of 24.0 to 32.5 kg/m². * Prediabetes, defined by at least one of the following: fasting plasma glucose of 5.6-6.9 mmol/L, 2-hour plasma glucose of 7.8-11.0 mmol/L during a 75-g oral glucose tolerance test, or glycated hemoglobin (HbA1c) of 5.7%-6.4%, without meeting diagnostic criteria for diabetes. * Not regularly meeting recommended exercise levels during the previous 3 months, defined as less than 150 minutes per week of moderate-intensity aerobic activity or an equivalent amount of moderate-to-vigorous aerobic activity, and resistance training on fewer than 2 days per week. * Able to perform activities of daily living independently and considered medically suitable to participate safely in moderate-intensity aerobic and resistance exercise. * Able to participate in the 12-week intervention and major study assessments. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Previously diagnosed diabetes, or diabetes-range glucose results at formal baseline screening confirmed by medical assessment. * Regular use within the previous 3 months of medications that may substantially affect glucose metabolism, body weight, or the primary outcome, including glucose-lowering medications, weight-loss medications, or systemic glucocorticoids. * Severe, acute, or inadequately controlled medical conditions that, in the judgment of the study medical team, would make exercise participation or exercise testing unsafe. * Severe musculoskeletal, neurological, cognitive, or psychiatric conditions that would interfere with safe participation in the intervention or study assessments. * Alcohol Use Disorders Identification Test (AUDIT) score ≥16, or clinically significant harmful alcohol use or alcohol dependence based on medical assessment. * Unintentional body weight change greater than 5% during the previous 6 months, or current participation in another structured intervention likely to substantially affect glucose metabolism, body weight, or physical activity. * Pregnancy, breastfeeding, planned pregnancy during the study period, or other circumstances expected to prevent completion of the 12-week intervention and primary outcome assessment.

Primary outcome measure(s)

  • Glycated Hemoglobin (HbA1c) at Week 12 — Week 12
    Glycated Hemoglobin (HbA1c) will be measured from a venous blood sample and reported as a percentage (%). The primary comparison will evaluate HbA1c at Week 12 between the randomized groups, with baseline HbA1c accounted for in the primary statistical analysis.

Trial sites (1)

FacilityCityRegionStatus
Jining Exercise and Health Promotion Center Jining Shandong

More China Institute of Sport Science trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07904962 on ClinicalTrials.gov ↗ ← All trials in China